Linked Life Data

19935676

Source:http://linkedlifedata.com/resource/pubmed/id/19935676

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-11-25
pubmed:abstractText
Epithelia are protected from adverse conditions by a mucous barrier. The secreted and transmembrane mucins that constitute the mucous barrier are largely unrecognized as effectors of carcinogenesis. However, both types of mucins are intimately involved in inflammation and cancer. Moreover, diverse human malignancies overexpress transmembrane mucins to exploit their role in signalling cell growth and survival. Mucins have thus been identified as markers of adverse prognosis and as attractive therapeutic targets. Notably, the findings that certain transmembrane mucins induce transformation and promote tumour progression have provided the experimental basis for demonstrating that inhibitors of their function are effective as anti-tumour agents in preclinical models.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1474-1768
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
874-85
pubmed:dateRevised
2011-2-14
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Mucins in cancer: function, prognosis and therapy.
pubmed:affiliation
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA. Donald_Kufe@dfci.harvard.edu
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural